A few weeks ago, Dr. Lecia Sequist, Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital (MGH), joined us for a live webinar we did in partnership with LUNGevity Foundation. Dr. Sequist and her colleagues at MGH have been at the forefront of research in EGFR mutations: her group was among the first to identify activating mutations and observe the correlation with response to EGFR tyrosine kinase inhibitors (TKIs), and they continue to do much of the leading clinical research on acquired resistance -- the development of progression after an initial good response -- and potential mechanisms for reversing this.

In the presentation below, provided in video and audio podcast forms (along with the associated transcript and figures), she provides an outline of the issue and some of the identified mechanisms for resistance. In addition, she discusses several attempts to manage this and current and emerging clinical trial options for this setting.

[powerpress]

sequist-acquired-resistance-to-egfr-tkis-audio-podcast

sequist-acquired-resistance-to-egfr-tkis-transcript

sequist-acquired-resistance-to-egfr-tkis-figures

It's worth noting that Dr. Sequist was unable to discuss the results from a just-published paper that describes the MGH experience of re-biopsying patients over the course of treatment, since that information was still confidential until its publication last week. She recorded a separate brief podcast with me just days ago that is currently in production as a second portion of the podcast, and we'll also include the Q&A exchange from this webinar later.